谷歌浏览器插件
订阅小程序
在清言上使用

A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers

JOURNAL FOR IMMUNOTHERAPY OF CANCER(2019)

引用 0|浏览18
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要